{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:07:24Z","timestamp":1762427244598,"version":"build-2065373602"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03093-6","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:32:25Z","timestamp":1761136345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimization of upfront therapy for adult acute lymphoblastic leukemia: a paradigm shift toward immunotherapy"],"prefix":"10.1007","volume":"42","author":[{"given":"Amr","family":"Hanbali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostafa","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Abdrabou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riad El","family":"Fakih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansour","family":"Alfayez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjali","family":"Advani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"issue":"1","key":"3093_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00525-x","volume":"10","author":"L Pagliaro","year":"2024","unstructured":"Pagliaro L, Chen SJ, Herranz D, et al. Acute lymphoblastic leukaemia. Nat Rev Dis Primers. 2024;10(1):41.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"3093_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2023.101485","volume":"36","author":"S Prockop","year":"2023","unstructured":"Prockop S, Wachter F. The current landscape: allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia. Best Pract Res Clin Haematol. 2023;36(3):101485.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"3093_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1365-2141.2010.08246.x","volume":"150","author":"JM Rowe","year":"2010","unstructured":"Rowe JM. Prognostic factors in adult acute lymphoblastic leukaemia. Br J Haematol. 2010;150(4):389\u2013405.","journal-title":"Br J Haematol"},{"issue":"2","key":"3093_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3727\/096504014X14146137738547","volume":"22","author":"K Ross","year":"2015","unstructured":"Ross K, Gillespie-Twardy AL, Agha M, et al. Intensive chemotherapy in patients aged 70 years or older newly diagnosed with acute myeloid leukemia. Oncol Res. 2015;22(2):85\u201392.","journal-title":"Oncol Res"},{"issue":"14","key":"3093_CR5","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","volume":"133","author":"W Stock","year":"2019","unstructured":"Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133(14):1548\u201359.","journal-title":"Blood"},{"issue":"21","key":"3093_CR6","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1002\/cncr.35505","volume":"130","author":"HM Kantarjian","year":"2024","unstructured":"Kantarjian HM, Boissel N, Papayannidis C, et al. Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: development, current status, and future directions. Cancer. 2024;130(21):3631\u201346.","journal-title":"Cancer"},{"key":"3093_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104317","volume":"196","author":"D Kegyes","year":"2024","unstructured":"Kegyes D, Ghiaur G, Bancos A, Tomuleasa C, Gale RP. Immune therapies of B-cell acute lymphoblastic leukaemia in children and adults. Crit Rev Oncol Hematol. 2024;196:104317.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"3093_CR8","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","volume":"105","author":"G Pavlasova","year":"2020","unstructured":"Pavlasova G, Mraz M. The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy. Haematologica. 2020;105(6):1494\u2013506.","journal-title":"Haematologica"},{"issue":"25","key":"3093_CR9","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.1182\/blood-2008-04-151860","volume":"113","author":"DA Thomas","year":"2009","unstructured":"Thomas DA, O\u2019Brien S, Jorgensen JL, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009;113(25):6330\u20137.","journal-title":"Blood"},{"issue":"21","key":"3093_CR10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/blood.V116.21.170.170","volume":"116","author":"D Hoelzer","year":"2010","unstructured":"Hoelzer D, Huettmann A, Kaul F, et al. Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high risk patients; results of 263 CD20+ patients studied prospectively in GMALL study 07\/2003. Blood. 2010;116(21):170\u2013170.","journal-title":"Blood"},{"issue":"11","key":"3093_CR11","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","volume":"375","author":"S Maury","year":"2016","unstructured":"Maury S, Chevret S, Thomas X, et al. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med. 2016;375(11):1044\u201353.","journal-title":"N Engl J Med"},{"issue":"24","key":"3093_CR12","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","volume":"28","author":"DA Thomas","year":"2010","unstructured":"Thomas DA, O\u2019Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28(24):3880\u20139.","journal-title":"J Clin Oncol"},{"key":"3093_CR13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123374","volume":"134","author":"DI Marks","year":"2019","unstructured":"Marks DI, Kirkwood AA, Rowntree CJ, et al. First analysis of the UKALL14 phase 3 randomised trial to determine if the addition of rituximab to standard induction chemotherapy improves EFS in adults with precursor B-ALL (CRUK\/09\/006). Blood. 2019;134:739.","journal-title":"Blood"},{"key":"3093_CR14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129884","volume":"134","author":"G Richard-Carpentier","year":"2019","unstructured":"Richard-Carpentier G, Kantarjian HM, Konopleva MY, et al. Phase II study of the hyper-CVAD regimen in combination with ofatumumab (HCVAD-O) as frontline therapy for adult patients (pts) with CD20-positive B-cell acute lymphoblastic leukemia (B-ALL). Blood. 2019;134:2577.","journal-title":"Blood"},{"key":"3093_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2020-142121","volume":"136","author":"K Morita","year":"2020","unstructured":"Morita K, Sasaki K, Richard-Carpentier G, et al. Comparison of hyper-CVAD plus ofatumumab to hyper-CVAD plus rituximab in patients with newly diagnosed Philadelphia chromosome-negative CD20-positive B-cell acute lymphoblastic leukemia: a propensity score analysis. Blood. 2020;136:42\u20133.","journal-title":"Blood"},{"issue":"10","key":"3093_CR16","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","volume":"55","author":"M Zhu","year":"2016","unstructured":"Zhu M, Wu B, Brandl C, et al. Blinatumomab, a bispecific T-cell engager (BiTE(\u00ae)) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications. Clin Pharmacokinet. 2016;55(10):1271\u201388.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"3093_CR17","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836\u201347.","journal-title":"N Engl J Med"},{"issue":"16","key":"3093_CR18","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","volume":"35","author":"G Martinelli","year":"2017","unstructured":"Martinelli G, Boissel N, Chevallier P, et al. Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with Blinatumomab: results from a phase II, single-arm. multicenter study. J Clin Oncol. 2017;35(16):1795\u2013802.","journal-title":"J Clin Oncol"},{"key":"3093_CR19","unstructured":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-granted-accelerated-approval-blinatumomab-blincyto-amgen-inc-treatment-adult-and-pediatric"},{"issue":"4","key":"3093_CR20","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2312948","volume":"391","author":"MR Litzow","year":"2024","unstructured":"Litzow MR, Sun Z, Mattison RJ, et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N Engl J Med. 2024;391(4):320\u201333.","journal-title":"N Engl J Med"},{"issue":"18","key":"3093_CR21","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","volume":"29","author":"MS Topp","year":"2011","unstructured":"Topp MS, Kufer P, G\u00f6kbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493\u20138.","journal-title":"J Clin Oncol"},{"issue":"11","key":"3093_CR22","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1080\/10428194.2020.1780583","volume":"61","author":"N G\u00f6kbuget","year":"2020","unstructured":"G\u00f6kbuget N, Zugmaier G, Dombret H, et al. Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2020;61(11):2665\u201373.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"3093_CR23","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Senapati J, et al. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023;10(6):e433\u201344.","journal-title":"Lancet Haematol"},{"issue":"3","key":"3093_CR24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/ajh.27576","volume":"100","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian H, Short NJ, Jain N, et al. Hyper-CVAD and sequential blinatumomab without and with inotuzumab in young adults with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. Am J Hematol. 2025;100(3):402\u20137.","journal-title":"Am J Hematol"},{"key":"3093_CR25","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1182\/blood-2023-174973","volume":"142","author":"S Chiaretti","year":"2023","unstructured":"Chiaretti S, Della Starza I, Santoro A, et al. Sequential chemotherapy and blinatumomab to improve minimal residual disease in adult Ph-B-lineage acute lymphoblastic leukemia. Final results of the phase II Gimema LAL2317 trial. Blood. 2023;142:826.","journal-title":"Blood"},{"key":"3093_CR26","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1182\/blood-2023-177847","volume":"142","author":"N Boissel","year":"2023","unstructured":"Boissel N, Huguet F, Leguay T, et al. Exploring the heterogeneity of response to blinatumomab in high-risk Philadelphia-negative B-cell precursor acute lymphoblastic leukemia: an analysis from the QUEST sub-study of the Graall-2014\/B trial. Blood. 2023;142:4349.","journal-title":"Blood"},{"issue":"S3","key":"3093_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000968372.81147.9d","volume":"7","author":"S Fleming","year":"2023","unstructured":"Fleming S, Reynolds J, Bajel A, et al. P365: sequential blinatumomab with reduced intensity chemotherapy for older adults with newly diagnosed Ph-B-precursor acute lymphoblastic leukemia\u2013final results of the ALLG ALL08 study. HemaSphere. 2023;7(S3):e811479d.","journal-title":"HemaSphere"},{"key":"3093_CR28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180472","volume":"142","author":"N Goekbuget","year":"2023","unstructured":"Goekbuget N, Schwartz S, Faul C, et al. Dose reduced chemotherapy in sequence with Blinatumomab for newly diagnosed older patients with Ph\/BCR: ABL negative B-precursor adult lymphoblastic leukemia (ALL): preliminary results of the GMALL bold trial. Blood. 2023;142:964.","journal-title":"Blood"},{"issue":"14","key":"3093_CR29","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1200\/JCO.21.01766","volume":"40","author":"AS Advani","year":"2022","unstructured":"Advani AS, Moseley A, O\u2019Dwyer KM, et al. SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. J Clin Oncol. 2022;40(14):1574\u201382.","journal-title":"J Clin Oncol"},{"issue":"20","key":"3093_CR30","doi-asserted-by":"publisher","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-11-0486","volume":"17","author":"AD Ricart","year":"2011","unstructured":"Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res. 2011;17(20):6417\u201327.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3093_CR31","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.23.00546","volume":"42","author":"M Stelljes","year":"2024","unstructured":"Stelljes M, Raffel S, Alakel N, et al. Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome-negative B-precursor ALL. J Clin Oncol. 2024;42(3):273\u201382.","journal-title":"J Clin Oncol"},{"issue":"36","key":"3093_CR32","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1200\/JCO.24.00490","volume":"42","author":"P Chevallier","year":"2024","unstructured":"Chevallier P, Leguay T, Delord M, et al. Inotuzumab ozogamicin and low-intensity chemotherapy in older patients with newly diagnosed CD22(+) Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. J Clin Oncol. 2024;42(36):4327\u201341.","journal-title":"J Clin Oncol"},{"key":"3093_CR33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-209438","volume":"144","author":"DJ DeAngelo","year":"2024","unstructured":"DeAngelo DJ, Yin J, Advani AS, et al. Addition of inotuzumab to a pediatric inspired chemotherapy regimen in young adult patients with B-cell acute lymphoblastic leukemia: findings from the Alliance A041501 phase 3 randomized trial. Blood. 2024;144:308.","journal-title":"Blood"},{"issue":"1","key":"3093_CR34","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1182\/asheducation-2016.1.580","volume":"2016","author":"EA Raetz","year":"2016","unstructured":"Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia. Hematology. 2016;2016(1):580\u20138.","journal-title":"Hematology"},{"issue":"5","key":"3093_CR35","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/ajh.26144","volume":"96","author":"K Morita","year":"2021","unstructured":"Morita K, Jain N, Kantarjian H, et al. Outcome of T-cell acute lymphoblastic leukemia\/lymphoma: focus on near-ETP phenotype and differential impact of nelarabine. Am J Hematol. 2021;96(5):589\u201398.","journal-title":"Am J Hematol"},{"issue":"12","key":"3093_CR36","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1080\/14737140.2023.2271662","volume":"23","author":"LH Miller","year":"2023","unstructured":"Miller LH, Maxa KL, Winter SS, Gossai NP. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia\/lymphoma: challenges, opportunities, and future directions. Expert Rev Anticancer Ther. 2023;23(12):1229\u201336.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"28","key":"3093_CR37","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1200\/JCO.20.00256","volume":"38","author":"KP Dunsmore","year":"2020","unstructured":"Dunsmore KP, Winter SS, Devidas M, et al. Children\u2019s oncology group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia. J Clin Oncol. 2020;38(28):3282\u201393.","journal-title":"J Clin Oncol"},{"key":"3093_CR38","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1182\/blood-2021-152355","volume":"138","author":"CJ Rowntree","year":"2021","unstructured":"Rowntree CJ, Kirkwood AA, Clifton-Hadley L, et al. First analysis of the UKALL14 randomized trial to determine whether the addition of nelarabine to standard chemotherapy improves event free survival in adults with T-cell acute lymphoblastic leukaemia (CRUK\/09\/006). Blood. 2021;138:366.","journal-title":"Blood"},{"issue":"21","key":"3093_CR39","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1182\/blood.2024024493","volume":"144","author":"T Bhatla","year":"2024","unstructured":"Bhatla T, Hogan LE, Teachey DT, et al. Daratumumab in pediatric relapsed\/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study. Blood. 2024;144(21):2237\u201347.","journal-title":"Blood"},{"issue":"9","key":"3093_CR40","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","volume":"4","author":"TN Chonghaile","year":"2014","unstructured":"Chonghaile TN, Roderick JE, Glenfield C, et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014;4(9):1074\u201387.","journal-title":"Cancer Discov"},{"issue":"6","key":"3093_CR41","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E, et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 2021;11(6):1440\u201353.","journal-title":"Cancer Discov"},{"issue":"7","key":"3093_CR42","first-page":"554","volume":"15","author":"J Wells","year":"2017","unstructured":"Wells J, Jain N, Konopleva M. Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype. Clin Adv Hematol Oncol. 2017;15(7):554\u201361.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"6","key":"3093_CR43","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00277-023-05241-2","volume":"102","author":"R Alghandour","year":"2023","unstructured":"Alghandour R, Sakr DH, Shaaban Y. Philadelphia-like acute lymphoblastic leukemia: the journey from molecular background to the role of bone marrow transplant-review article. Ann Hematol. 2023;102(6):1287\u2013300.","journal-title":"Ann Hematol"},{"issue":"16","key":"3093_CR44","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1182\/blood.2019001244","volume":"134","author":"I Tanasi","year":"2019","unstructured":"Tanasi I, Ba I, Sirvent N, et al. Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. Blood. 2019;134(16):1351\u20135.","journal-title":"Blood"},{"issue":"10","key":"3093_CR45","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.3324\/haematol.2021.278697","volume":"106","author":"LM Niswander","year":"2021","unstructured":"Niswander LM, Loftus JP, Lainey \u00c9, et al. Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia. Haematologica. 2021;106(10):2763\u20137.","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"3093_CR46","doi-asserted-by":"publisher","first-page":"6117","DOI":"10.1182\/blood-2022-164699","volume":"140","author":"SK Tasian","year":"2022","unstructured":"Tasian SK, Hunter DS, Chen I-ML, et al. A phase 2 study of ruxolitinib with chemotherapy in children with Philadelphia chromosome-like acute lymphoblastic leukemia (AALL1521\/INCB18424-269): biologic characteristics and minimal residual disease response of patients with non-CRLF2-rearranged JAK pathway alterations. Blood. 2022;140(Supplement 1):6117\u20138.","journal-title":"Blood"},{"issue":"9","key":"3093_CR47","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1182\/blood-2004-07-2922","volume":"105","author":"M Mancini","year":"2005","unstructured":"Mancini M, Scappaticci D, Cimino G, et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood. 2005;105(9):3434\u201341.","journal-title":"Blood"},{"issue":"12","key":"3093_CR48","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1002\/cncr.20668","volume":"101","author":"H Kantarjian","year":"2004","unstructured":"Kantarjian H, Thomas D, O\u2019Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101(12):2788\u2013801.","journal-title":"Cancer"},{"issue":"20","key":"3093_CR49","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1200\/JCO.2004.10.050","volume":"22","author":"X Thomas","year":"2004","unstructured":"Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22(20):4075\u201386.","journal-title":"J Clin Oncol"},{"issue":"12","key":"3093_CR50","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","volume":"106","author":"JM Rowe","year":"2005","unstructured":"Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993. Blood. 2005;106(12):3760\u20137.","journal-title":"Blood"},{"issue":"6","key":"3093_CR51","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","volume":"100","author":"OG Ottmann","year":"2002","unstructured":"Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002;100(6):1965\u201371.","journal-title":"Blood"},{"issue":"12","key":"3093_CR52","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3324\/haematol.2016.144535","volume":"101","author":"S Chiaretti","year":"2016","unstructured":"Chiaretti S, Vitale A, Vignetti M, et al. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. Haematologica. 2016;101(12):1544\u201352.","journal-title":"Haematologica"},{"issue":"17","key":"3093_CR53","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","volume":"383","author":"R Fo\u00e0","year":"2020","unstructured":"Fo\u00e0 R, Bassan R, Vitale A, et al. Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383(17):1613\u201323.","journal-title":"N Engl J Med"},{"issue":"8","key":"3093_CR54","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1200\/JCO.23.01075","volume":"42","author":"R Fo\u00e0","year":"2024","unstructured":"Fo\u00e0 R, Bassan R, Elia L, et al. Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL. J Clin Oncol. 2024;42(8):881\u20135.","journal-title":"J Clin Oncol"},{"issue":"36","key":"3093_CR55","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1200\/JCO.24.00272","volume":"42","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian H, Short NJ, Haddad FG, et al. Results of the simultaneous combination of ponatinib and blinatumomab in Philadelphia chromosome-positive ALL. J Clin Oncol. 2024;42(36):4246\u201351.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3093_CR56","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N, et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023;10(1):e24\u201334.","journal-title":"Lancet Haematol"},{"issue":"10","key":"3093_CR57","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1002\/cncr.22631","volume":"109","author":"OG Ottmann","year":"2007","unstructured":"Ottmann OG, Wassmann B, Pfeifer H, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer. 2007;109(10):2068\u201376.","journal-title":"Cancer"},{"issue":"7","key":"3093_CR58","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.3324\/haematol.2020.260935","volume":"106","author":"S Chiaretti","year":"2021","unstructured":"Chiaretti S, Ansuinelli M, Vitale A, et al. A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol. Haematologica. 2021;106(7):1828\u201338.","journal-title":"Haematologica"},{"issue":"3","key":"3093_CR59","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1182\/bloodadvances.2016001495","volume":"1","author":"F Ravandi","year":"2016","unstructured":"Ravandi F, Othus M, O\u2019Brien SM, et al. US intergroup study of chemotherapy plus Dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. Blood Adv. 2016;1(3):250\u20139.","journal-title":"Blood Adv"},{"issue":"6","key":"3093_CR60","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1182\/blood-2015-03-636548","volume":"126","author":"DY Kim","year":"2015","unstructured":"Kim DY, Joo YD, Lim SN, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood. 2015;126(6):746\u201356.","journal-title":"Blood"},{"key":"3093_CR61","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2460737","author":"F Lang","year":"2025","unstructured":"Lang F, Voss A, Kobbe G, et al. Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia. Leuk Lymphoma. 2025. https:\/\/doi.org\/10.1080\/10428194.2025.2460737.","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"3093_CR62","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1002\/cncr.30231","volume":"122","author":"K Sasaki","year":"2016","unstructured":"Sasaki K, Jabbour EJ, Ravandi F, et al. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis. Cancer. 2016;122(23):3650\u20136.","journal-title":"Cancer"},{"issue":"18","key":"3093_CR63","doi-asserted-by":"publisher","first-page":"5395","DOI":"10.1182\/bloodadvances.2022007764","volume":"6","author":"JM Ribera","year":"2022","unstructured":"Ribera JM, Garc\u00eda-Calduch O, Ribera J, et al. Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Adv. 2022;6(18):5395\u2013402.","journal-title":"Blood Adv"},{"issue":"21","key":"3093_CR64","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1001\/jama.2024.4783","volume":"331","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian HM, Aldoss I, et al. Ponatinib vs imatinib in frontline Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2024;331(21):1814\u201323.","journal-title":"JAMA"},{"issue":"23","key":"3093_CR65","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1002\/cncr.29646","volume":"121","author":"F Ravandi","year":"2015","unstructured":"Ravandi F, O\u2019Brien SM, Cortes JE, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015;121(23):4158\u201364.","journal-title":"Cancer"},{"issue":"12","key":"3093_CR66","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1016\/S2352-3026(18)30176-5","volume":"5","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Short NJ, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 2018;5(12):e618\u201327.","journal-title":"Lancet Haematol"},{"issue":"6","key":"3093_CR67","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/annonc\/mdw123","volume":"27","author":"JH Yoon","year":"2016","unstructured":"Yoon JH, Yhim HY, Kwak JY, et al. Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Oncol. 2016;27(6):1081\u20138.","journal-title":"Ann Oncol"},{"issue":"11","key":"3093_CR68","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1038\/leu.2012.164","volume":"26","author":"S Lee","year":"2012","unstructured":"Lee S, Kim DW, Cho BS, et al. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 2012;26(11):2367\u201374.","journal-title":"Leukemia"},{"issue":"4","key":"3093_CR69","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/sj.leu.2403683","volume":"19","author":"F Pane","year":"2005","unstructured":"Pane F, Cimino G, Izzo B, et al. Significant reduction of the hybrid BCR\/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Leukemia. 2005;19(4):628\u201335.","journal-title":"Leukemia"},{"issue":"4","key":"3093_CR70","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","volume":"128","author":"NJ Short","year":"2016","unstructured":"Short NJ, Jabbour E, Sasaki K, et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016;128(4):504\u20137.","journal-title":"Blood"},{"issue":"20","key":"3093_CR71","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1182\/blood.2022016194","volume":"140","author":"A Ghobadi","year":"2022","unstructured":"Ghobadi A, Slade M, Kantarjian H, et al. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. Blood. 2022;140(20):2101\u201312.","journal-title":"Blood"},{"key":"3093_CR72","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1182\/blood-2023-180204","volume":"142","author":"AS Advani","year":"2023","unstructured":"Advani AS, Moseley AB, O\u2019Dwyer KM, et al. Long-term follow up for SWOG 1318: combination of Dasatinib, prednisone, and Blinatumomab for older patients with Philadelphia-chromosome (Ph) positive acute lymphoblastic leukemia (ALL). Blood. 2023;142:1499.","journal-title":"Blood"},{"key":"3093_CR73","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/01.HS9.0000844300.04335.af","volume":"6","author":"S Chiaretti","year":"2022","unstructured":"Chiaretti S, Bassan R, Vitale A, et al. P353: forty months update of the GIMEMA LAL2116 (D-Alba) protocol and ancillary LAL2217 study for newly diagnosed adult Ph+ ALL. HemaSphere. 2022;6:253\u20134.","journal-title":"HemaSphere"},{"key":"3093_CR74","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-206602","volume":"144","author":"NJ Short","year":"2024","unstructured":"Short NJ, Kantarjian H, Jain N, et al. Blinatumomab and ponatinib for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: updated results and predictors of relapse. Blood. 2024;144:837.","journal-title":"Blood"},{"key":"3093_CR75","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1182\/blood-2024-207892","volume":"144","author":"S Chiaretti","year":"2024","unstructured":"Chiaretti S, Leoncin M, Elia L, et al. Efficacy and toxicity of frontline Ponatinib plus Blinatumomab for adult Ph+ ALL patients of all ages. Intermediate analysis of the Gimema ALL2820. Blood. 2024;144:835.","journal-title":"Blood"},{"issue":"6","key":"3093_CR76","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1182\/blood.2024025800","volume":"145","author":"MR Luskin","year":"2025","unstructured":"Luskin MR, Murakami MA, Keating J, et al. Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia. Blood. 2025;145(6):577\u201389.","journal-title":"Blood"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03093-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03093-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03093-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:03:57Z","timestamp":1762427037000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03093-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":76,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["3093"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03093-6","relation":{},"ISSN":["1559-131X"],"issn-type":[{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"526"}}